Adverse Outcomes and Mortality in Users of Non-Steroidal Anti-Inflammatory Drugs tested positive for SARS-CoV-2: A Danish Nationwide Cohort Study

# **Online Supplementary Material**

**Table S1** Univariate association with death (RRcd) and use of NSAIDs (RRce) for each covariate in the propensity score

**Table S2** Association between current NSAID use and mortality, intensive care unit admission, mechanical ventilation, renal replacement therapy and hospitalisation using an outcome assessment window for death of 60 days and 30 days for secondary outcomes.

**Table S3** Association between use of NSAIDs within 60 days before cohort entry and 30-day mortality, intensive care unit admission, mechanical ventilation, renal replacement therapy and hospitalisation

**Table S4** Association between NSAID prescription fills within 60 days to 14 days before cohort entry and 30-day mortality, intensive care unit admission, mechanical ventilation, renal replacement therapy and hospitalisation

Appendix A Codes used to define exposure, outcome, and covariate variables

 $\textbf{Table S1} \ \textbf{Univariate association with death (RRcd) and use of NSAIDs (RRce) for each covariate in the propensity score$ 

Covariate	RR(ce)	RR(cd)
Prescription drug use		
Antihypertensives	0.93 (0.67-1.30)	1.44 (1.14-1.80)
Antidiabetic drugs	1.22 (0.79-1.86)	1.60 (1.24-2.08)
Low-dose aspirin	0.85 (0.50-1.45)	1.22 (0.94-1.59)
Immunosuppressants	1.54 (0.48-4.94)	1.49 (0.63-3.51)
Opioids	2.38 (1.72-3.30)	2.18 (1.75-2.73)
Benzodiazepines	0.86 (0.42-1.77)	2.70 (1.90-3.84)
Z-drugs	0.78 (0.41-1.50)	1.60 (1.16-2.20)
1st gen. antipsychotics	0.52 (0.07-3.78)	3.53 (1.74-7.13)
2nd generation antipsychotics	0.40 (0.13-1.27)	3.52 (2.38-5.21)
Systemic glucocorticoids	1.40 (0.86-2.28)	1.73 (1.28-2.33)
Inhaled corticosteroids	1.52 (1.01-2.29)	1.41 (1.02-1.96)
Prior diagnoses		
Asthma	0.94 (0.56-1.57)	1.15 (0.76-1.73)
COPD	0.83 (0.44-1.56)	1.80 (1.36-2.38)
Cardiovascular disease	0.57 (0.37-0.87)	1.42 (1.15-1.75)
Stroke	0.63 (0.31-1.25)	1.15 (0.86-1.52)
Chronic kidney disease	0.23 (0.03-1.65)	2.67 (1.68-4.24)
Liver disease	1.05 (0.39-2.88)	2.49 (1.33-4.66)
Alcohol related disorders	0.70 (0.29-1.72)	2.20 (1.43-3.39)
Dementia	0.33 (0.08-1.34)	1.66 (1.15-2.42)
Cancer	0.96 (0.60-1.53)	1.37 (1.06-1.75)
Overweight or obesity	1.55 (1.06-2.27)	1.52 (1.08-2.16)
Hemiplegia and paraplegia	0.91 (0.12-6.71)	6.99 (2.65-18.42)
Osteoarthrosis	1.49 (1.05-2.11)	1.01 (0.80-1.27)
Rheumatoid athritis	1.82 (1.09-3.04)	1.11 (0.76-1.64)
Dysmenorrhoea	4.32 (1.94-9.63)	-

**Table S2** Association between current NSAID use and mortality, intensive care unit admission, mechanical ventilation, renal replacement therapy and hospitalisation using an outcome assessment window for death of 60 days 30 days for secondary outcomes

#### **Unmatched cohort**

	Treated		Untreated		Comparison	
					Risk	_
Outcome	<b>Events</b>	Risk (%)	<b>Events</b>	Risk (%)	difference (%)	Risk ratio
Death	14/248	5.6 (2.8-8.5)	564/8988	6.3 (5.8-6.8)	-0.6 (-3.5-2.3)	0.90 (0.54-1.51)
Hospitalisation**	57/228	25.0 (19.4-30.6)	1512/8414	18.0 (17.1-18.8)	7.0 (1.3-12.7)	1.39 (1.11-1.75)
ICU-admission**	12/247	4.9 (2.2-7.5)	291/8956	3.2 (2.9-3.6)	1.6 (-1.1-4.3)	1.50 (0.85-2.63)
Mechanical ventilation**	10/248	4.0 (1.6-6.5)	232/8970	2.6 (2.3-2.9)	1.4 (-1.0-3.9)	1.56 (0.84-2.90)
Renal replacement therapy**	n<5/248	_***	_***	_***	0.4 (-1.0-1.8)	1.49 (0.47-4.69)

## Matched cohort

	Treated		Untreated		Comparison	
					Risk	_
Outcome	<b>Events</b>	Risk (%)	<b>Events</b>	Risk (%)	difference (%)	Risk ratio
Death	14/224	6.3 (3.1-9.4)	62/896	6.9 (5.1-8.7)	-0.7 (-4.3-3.0)	0.90 (0.51-1.60)
Hospitalisation	50/204	24.5 (18.6-30.4)	183/826	22.2 (19.0-25.3)	2.4 (-4.3-9.1)	1.11 (0.84-1.46)
ICU-admission	12/223	5.4 (2.4-8.3)	42/889	4.7 (3.2-6.2)	0.7 (-2.7-4.0)	1.14 (0.60-2.16)
Mechanical ventilation	10/224	4.5 (1.8-7.2)	35/891	3.9 (2.5-5.3)	0.5 (-2.5-3.6)	1.14 (0.56-2.30)
Renal replacement therapy	n<5/224	_***	_***	_***	-0.3 (-2.1-1.5)	0.80 (0.22-2.85)

<sup>\*</sup>NSAID use was defined as a filled prescription within 30 days prior to the date cohort entry.

<sup>\*\*</sup> Patients with a secondary outcome occurring during the outcome assessment window were excluded, resulting in exclusion of n=594 patients for hospitalisation, n=33 for ICU-admission, n=18 for mechanical ventilation, and n=6 for renal replacement therapy.

<sup>\*\*\*</sup> Censored to preserve anonymity for counts n<5

**Table S3** Association between use of NSAIDs within 60 days before cohort entry and 30-day mortality, intensive care unit admission, mechanical ventilation, renal replacement therapy and hospitalisation

## **Unmatched cohort**

	Treated		Untreated		Comparison	
					Risk	_
Outcome	<b>Events</b>	Risk (%)	<b>Events</b>	Risk (%)	difference (%)	Risk ratio
Death	24/445	5.4 (3.3-7.5)	511/8791	5.8 (5.3-6.3)	-0.4 (-2.6-1.7)	0.93 (0.62-1.38)
Hospitalisation**	90/406	22.2 (18.1-26.2)	1422/8236	17.3 (16.4-18.1)	4.9 (0.8-9.0)	1.28 (1.06-1.55)
ICU-admission**	20/443	4.5 (2.6-6.5)	270/8760	3.1 (2.7-3.4)	1.4 (-0.5-3.4)	1.46 (0.94-2.28)
Mechanical ventilation**	17/444	3.8 (2.0-5.6)	218/8774	2.5 (2.2-2.8)	1.3 (-0.5-3.2)	1.54 (0.95-2.50)
Renal replacement therapy**	n<5/445	_***	_***	_***	0.3 (-0.6-1.1)	1.39 (0.50-3.80)

## Matched cohort

	Treated		Untreated		Comparison	_
					Risk	
Outcome	<b>Events</b>	Risk (%)	<b>Events</b>	Risk (%)	difference (%)	Risk ratio
Death	21/402	5.2 (3.0-7.4)	83/1608	5.2 (4.0-6.3)	0.1 (-2.4-2.5)	1.01 (0.63-1.63)
Hospitalisation	79/370	21.4 (17.2-25.5)	261/1493	17.5 (15.2-19.7)	3.9 (-0.9-8.6)	1.22 (0.97-1.54)
ICU-admission	19/400	4.7 (2.7-6.8)	62/1598	3.9 (2.8-4.9)	0.9 (-1.5-3.2)	1.22 (0.73-2.05)
Mechanical ventilation	16/401	4.0 (2.1-5.9)	52/1603	3.2 (2.3-4.2)	0.7 (-1.4-2.9)	1.23 (0.70-2.16)
Renal replacement therapy	n<5/402	_***	_***	_***	0.1 (-1.1-1.2)	1.07 (0.34-3.34)

<sup>\*</sup>NSAID use was defined as a filled prescription within 60 days prior to the date cohort entry.

<sup>\*\*</sup> Patients with a secondary outcome occurring during the outcome assessment window were excluded, resulting in exclusion of n=594 patients for hospitalisation, n=33 for ICU-admission, n=18 for mechanical ventilation, and n=6 for renal replacement therapy.

<sup>\*\*\*</sup> Censored to preserve anonymity for counts n<5

**Table S4** Association between NSAID prescription fills within 60 days to 14 days before cohort entry and 30-day mortality, intensive care unit admission, mechanical ventilation, renal replacement therapy and hospitalisation

#### **Unmatched** cohort

	Treated		Untreated		Comparison	
					Risk	_
Outcome	<b>Events</b>	Risk (%)	<b>Events</b>	Risk (%)	difference (%)	Risk ratio
Death	17/350	4.9 (2.6-7.1)	518/8886	5.8 (5.3-6.3)	-1.0 (-3.3-1.3)	0.83 (0.52-1.33)
Hospitalisation**	67/319	21.0 (16.5-25.5)	1445/8323	17.4 (16.5-18.2)	3.6 (-0.9-8.2)	1.21 (0.97-1.50)
ICU-admission**	16/348	4.6 (2.4-6.8)	274/8855	3.1 (2.7-3.5)	1.5 (-0.7-3.7)	1.49 (0.91-2.43)
Mechanical ventilation**	13/349	3.7 (1.7-5.7)	222/8869	2.5 (2.2-2.8)	1.2 (-0.8-3.2)	1.49 (0.86-2.58)
Renal replacement therapy**	n<5/350	_***	_***	_***	0.2 (-0.8-1.2)	1.31 (0.41-4.17)

## Matched cohort

	Treated		Untreated		Comparison	
					Risk	
Outcome	<b>Events</b>	Risk (%)	<b>Events</b>	Risk (%)	difference (%)	Risk ratio
Death	14/312	4.5 (2.2-6.8)	74/1248	5.9 (4.6-7.3)	-1.4 (-4.1-1.2)	0.76 (0.43-1.33)
Hospitalisation	60/287	20.9 (16.2-25.6)	191/1158	16.5 (14.2-18.8)	4.4 (-0.8-9.7)	1.27 (0.97-1.65)
ICU-admission	15/310	4.8 (2.4-7.2)	50/1241	4.0 (2.8-5.2)	0.8 (-1.9-3.5)	1.20 (0.68-2.13)
Mechanical ventilation	12/311	3.9 (1.7-6.0)	42/1244	3.4 (2.3-4.5)	0.5 (-1.9-2.9)	1.14 (0.60-2.17)
Renal replacement therapy	n<5/312	_***	_***	_***	-0.1 (-1.3-1.2)	0.92 (0.26-3.33)

<sup>\*</sup>NSAID use was defined as a filled prescription within 60 days to 14 days prior to the date cohort entry.

<sup>\*\*</sup> Patients with a secondary outcome occurring during the outcome assessment window were excluded, resulting in exclusion of n=594 patients for hospitalisation, n=33 for ICU-admission, n=18 for mechanical ventilation, and n=6 for renal replacement therapy.

<sup>\*\*\*</sup> Censored to preserve anonymity for counts n<5

# APPENDIX A

VARIABLE	CODING SYSTEM	CODE
Exposures		
NSAID	ATC	M01A (excluding M01AX)
Prescription drug use		-
Antihypertensives	ATC	C08, C03CA, C07, C09
Antidiabetic drugs	ATC	A10
Low-dose aspirin	ATC	B01AC06, B01AC30, N02BA01
Immunosuppressants	ATC	L04
Opioids	ATC	N02A
Benzodiazepines	ATC	N05BA, N05CD
Z-drugs (Non-benzodiazepine	ATC	N05CF
benzodiazepine receptor agonists)		
1st gen. antipsychotics	ATC	N05AA, N05AB, N05AC, N05AD, N05AF, N05AG, N05AL01
2nd gen. antipsychotics	ATC	N05AE, N05AH, N05AX, N05AL05
Systemic glucocorticoids	ATC	H02AB
Inhaled corticosteroids	ATC	R03BA01-09, R03AK06-08, R03AK10, R03AK11
History of		
Asthma	ICD-10	J45, J46
Chronic obstructive pulmonary disease	ICD-10	J41-J44
Cardiovascular disease	ICD-10	I20-I25, I47-I50
Ischaemic stroke	ICD-10	I63, I64
Chronic kidney disease	ICD-10	N00, N01, N03-N06, N08.8, N14.1, N14.2, N16.8, N17, N25.1, N26, N27
Liver disease	ICD-10	B18, K70.0- K70.3, K709, K71, K73, K74, K76.0, B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85
Alcohol related disorders	ICD-10	F10, E24.4, G31.2, G62.1, G72.1, I42.6, K29.2, K70, K85.2, K86.0, Q86.0, Z50.2, Z71.4, Z72.1
Dementia	ICD-10	F01-F04
Cancer	ICD-10	C00-C97, excluding C44
Overweight or obesity	ICD-10	E66
Hemiplegia and paraplegia	ICD-10	G04.1, G11.4, G80.1, G80.2, G83.0-G83.4, G83.9
Osteoarthrosis	ICD-10	M15-19
Rheumatoid arthritis/collagen vascular	ICD-10	L94.0, L94.1, L94.3, M05, M06, M08, M12.0,
disorders		M12.3, M30, M31.0 - M31.3, M32-M35, M45, M46.1, M46.8, M46.9
Dysmenorrhoea	ICD-10	N94.4-94.6
Other		

Phase of the outbreak	Calendar time	An indicator variable for whether the
		patient was tested before or after March 12,
		2020 where the strategy changed from
		focusing on containment with contact
		tracing and testing to a mitigation strategy
		prioritizing testing of patients with severe
		symptoms, admitted patients, and health
		care professionals
Outcomes		
Admission to intensive care unit	SKS	NABB, NABE
Mechanical ventilation	SKS	BGDA
Acute renal replacement therapy	SKS	BJFD0

REGISTRY	CITATION	INFORMATION OBTAINED	VARIABLES
Danish National Prescription Registry (Læmiddelmiddelstatistik registeret)	Pottegård et al (doi:10.1093/ije/dyw213)	All redeemed prescriptions from community pharmacies in the period 1995-2018	ATC-code, fill date
Danish National Patient Registry (Landspatientregisteret)	Schmidt et al (doi:10.2147/CLEP.S91125)	In- and outpatient hospital diagnoses in the period 1977-2018	ICD-10 code, admission date, intensive care unit admission, mechanical ventilation, renal replacement therapy
Civil Registration System (CPR-registeret)	Schmidt et al (doi:10.2147/CLEP.S179083)	Age, sex, migration- and vital status	,
The Danish Register of Causes of Death	Helweg-Larsen et al (doi:10.1177/1403494811399958)	Date of death	Date of death